Evenity (Romosozumab) Cost in Maryland: 2026 Prices, Insurance, and Savings

What Does Evenity Cost at Maryland Pharmacies in 2026?

The manufacturer list price for a single monthly dose of Evenity is $1,825, and Maryland retail pharmacies generally charge this same amount for cash-pay patients. A full course runs 12 monthly subcutaneous injections, placing the total treatment cost near $21,900 before insurance or discount programs.

That price reflects the two 105 mg/1.17 mL prefilled syringes administered together each month (total dose: 210 mg). Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. The FDA approved Evenity in April 2019 based on data from the FRAME and ARCH trials, both of which demonstrated significant fracture risk reduction in postmenopausal women with osteoporosis. In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months [1]. The drug's bone-forming mechanism is distinct from antiresorptive agents like denosumab and bisphosphonates, which is partly why the price remains high. No generic or biosimilar version of romosozumab is available in the United States as of mid-2026.

Prices at Maryland pharmacies can vary by a small margin depending on the dispensing location, but the cash-pay figure holds relatively steady statewide. Specialty pharmacies affiliated with Johns Hopkins, University of Maryland Medical System, and MedStar may apply facility-based markups for in-office administration. Patients receiving injections at a hospital outpatient clinic should expect a separate administration fee on top of the drug cost.

Does Maryland Medicaid Cover Evenity?

Yes. Maryland Medicaid covers Evenity for severe osteoporosis, though the state requires prior authorization before dispensing.

The PA process typically requires documentation of a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip on dual-energy X-ray absorptiometry (DXA). Prescribers must also demonstrate that the patient faces high fracture risk, which Maryland's Medicaid program generally defines as a history of fragility fracture, a FRAX 10-year major osteoporotic fracture probability exceeding 20%, or both. A step-therapy requirement may apply. Some Medicaid managed care organizations (MCOs) operating in Maryland, including Priority Partners and Jai Medical Systems, require trial and failure of at least one bisphosphonate or denosumab before approving romosozumab [2].

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has noted: "Romosozumab represents a true anabolic window. The 12-month treatment course builds bone rapidly, and the gains are best preserved by transitioning promptly to an antiresorptive agent" [3]. This sequencing strategy, romosozumab first followed by denosumab or a bisphosphonate, is now reflected in the 2020 Endocrine Society guidelines and is the protocol Maryland Medicaid expects prescribers to follow.

Processing times for PA in Maryland Medicaid average 5 to 10 business days. Urgent requests can be expedited within 24 hours if the prescriber documents imminent fracture risk.

Which Commercial Insurance Plans Cover Evenity in Maryland?

Most major commercial insurers in Maryland include Evenity on their specialty-tier formularies, but cost-sharing varies widely. CareFirst BlueCross BlueShield, the state's dominant carrier, lists Evenity as a specialty drug with coinsurance ranging from 20% to 40% after deductible.

At 30% coinsurance and a $1,825 monthly cost, a patient's share would be $547.50 per injection before reaching an out-of-pocket maximum. Maryland's benchmark silver plan under the ACA caps individual out-of-pocket spending at $9,200 for 2026 [4]. Patients with high-deductible plans may face the full $1,825 for early doses until deductible satisfaction.

UnitedHealthcare, Aetna, and Cigna plans sold on the Maryland Health Benefit Exchange also cover romosozumab with prior authorization. The PA criteria across commercial plans are broadly similar to Medicaid's: documented osteoporosis with DXA-confirmed T-score of -2.5 or below and evidence of high fracture risk. Some plans additionally require that the prescriber be an endocrinologist or rheumatologist, or that the patient be enrolled in a specialty pharmacy network.

Medicare Part B covers romosozumab when administered in a physician's office under the "incident to" billing pathway (HCPCS code J3111). The 2026 Medicare allowable amount for romosozumab is approximately $1,740 per dose, with the patient responsible for the standard 20% coinsurance ($348) after meeting the Part B deductible of $257 [5]. Medicare Advantage plans may apply different cost-sharing structures.

For patients with Medicare Part D coverage who self-administer at home (uncommon for romosozumab, since most patients receive injections at their provider's office), the catastrophic coverage threshold applies after $8 to 000 in true out-of-pocket spending under the Inflation Reduction Act provisions.

How the Amgen/UCB Evenity Savings Card Works

Amgen and UCB offer a co-pay assistance card for commercially insured patients that can reduce out-of-pocket costs to as little as $5 per monthly injection, subject to annual and per-patient caps.

The Evenity Complete savings program is available to patients with commercial insurance who have a valid prescription. Patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state healthcare program are ineligible for the commercial savings card. The program typically covers up to $15,000 per calendar year in co-pay or coinsurance costs, which is sufficient to offset the patient share for the entire 12-month course for most commercially insured individuals.

Enrollment requires a simple activation process: the prescribing physician's office or the dispensing specialty pharmacy submits the patient's insurance information to the program. The savings card is then applied at the point of sale. Patients who fill through specialty pharmacy networks like Accredo, BriovaRx, or Optum Specialty may have the card applied automatically.

A few caveats deserve attention. The savings card does not reduce the list price of the drug; it reduces only the patient's cost-sharing obligation. Amounts covered by the card generally do not count toward the patient's insurance deductible or out-of-pocket maximum, depending on the plan's accumulator adjustment policy. Maryland has not yet enacted accumulator adjustment legislation, so patients should verify how their plan handles manufacturer co-pay assistance [6].

Amgen also operates a patient assistance program (PAP) for uninsured patients or those who have exhausted insurance options. The PAP provides Evenity at no cost to qualifying patients with household incomes below 300% of the federal poverty level ($46,060 for an individual in 2026).

Is Compounded Romosozumab Legal in Maryland?

Licensed 503A compounding pharmacies in Maryland can legally prepare romosozumab formulations. This pathway exists under federal law as outlined in Section 503A of the Federal Food, Drug, and Cosmetic Act.

Under 503A rules, a compounding pharmacy must prepare the drug based on a valid, patient-specific prescription. The compounded product cannot be "essentially a copy" of a commercially available drug unless the prescriber documents that the FDA-approved product is medically inappropriate for that specific patient. This is a meaningful restriction. In practice, a prescriber would need to document a clinical reason why the commercially manufactured Evenity product does not meet the patient's needs (for example, an allergy to an inactive ingredient in the prefilled syringe formulation).

Maryland regulates compounding pharmacies through the Maryland Board of Pharmacy. The Board requires 503A pharmacies to maintain current licensure, comply with USP <797> and USP <800> standards for sterile compounding, and submit to regular inspections. Patients considering a compounded romosozumab product should confirm the pharmacy holds an active Maryland compounding license and has experience with monoclonal antibody preparations.

The cost of compounded romosozumab, if available from a qualifying 503A pharmacy, could differ substantially from the branded product. Pricing is set by the compounding pharmacy and is not standardized.

Can I Get Evenity via Telehealth in Maryland?

Maryland permits telehealth prescribing of Evenity. A licensed prescriber can evaluate the patient, review DXA results and fracture history, and issue a prescription during a video or audio visit.

Maryland's Telehealth Access Act established a permanent framework for telehealth prescribing after the COVID-era temporary expansions. The law requires that the prescriber hold an active Maryland medical license (or a license under an interstate compact that covers Maryland). The prescriber-patient relationship can be established via telehealth without a prior in-person visit.

The prescription itself can be sent electronically to a specialty pharmacy for dispensing. However, the actual injections still require either an in-person clinical visit or training for self-administration. Most patients receive romosozumab at their provider's office. The drug is supplied as two prefilled syringes that are injected subcutaneously in the abdomen, thigh, or upper arm. Each injection takes about one minute, and the second syringe must be administered immediately after the first.

For patients in rural parts of Maryland, including the Eastern Shore and western Allegany and Garrett counties where osteoporosis specialists may be sparse, telehealth can eliminate travel to Baltimore or the Washington, D.C., suburbs for the prescribing visit. The injections themselves can be given at a local primary care office or infusion center.

Saving Money on Evenity in Maryland: A Cost-Reduction Checklist

Several strategies can reduce the real cost of romosozumab for Maryland patients. Some are straightforward. Others require coordination between the prescriber, pharmacy, and insurer.

Step 1: Confirm insurance coverage and PA requirements. Call the number on the back of the insurance card and ask whether romosozumab (HCPCS J3111) requires prior authorization, and what documentation is needed. Request the PA form be sent to the prescriber's office.

Step 2: Apply for the Amgen/UCB co-pay card. Commercially insured patients should enroll in the Evenity Complete program before the first injection. The prescriber's office can handle enrollment during the PA submission process.

Step 3: Explore patient assistance if uninsured. Patients without insurance or with denied claims should contact Amgen's patient assistance program at 1-800-272-9376. Income documentation will be required.

Step 4: Compare pharmacy pricing. Maryland specialty pharmacies may quote slightly different dispensing fees. Patients with flexibility should request quotes from at least two pharmacies. GoodRx and RxSaver discount cards may also apply, though savings on specialty biologics are typically modest.

Step 5: Ask about medical benefit vs. pharmacy benefit. If the plan covers Evenity under the medical benefit (buy-and-bill at the physician's office), the cost-sharing structure may differ from pharmacy benefit coverage. Some patients find lower out-of-pocket costs under one pathway versus the other.

The ARCH trial's efficacy data supports the clinical value of completing the full 12-dose course. In that study, the 48% relative risk reduction in new vertebral fractures at 24 months was observed in patients who received 12 monthly doses of romosozumab before transitioning to alendronate [1]. Interrupting the course to save money could compromise fracture protection. The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recommend completing the full anabolic treatment window before switching to an antiresorptive [7].

ARCH Trial: The Evidence Behind Evenity's Price

The ARCH trial (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk) is the primary efficacy trial supporting romosozumab's clinical use and, by extension, its pricing.

Published in the New England Journal of Medicine in 2017, ARCH randomized 4,093 postmenopausal women with osteoporosis and a prior fragility fracture to receive either romosozumab 210 mg monthly for 12 months followed by alendronate, or alendronate alone for the full study duration [1]. At the primary endpoint of 24 months, the romosozumab-to-alendronate group showed a 48% lower risk of new vertebral fracture (P<0.001) and a 19% lower risk of nonvertebral fracture compared with alendronate alone.

The FRAME trial (Fracture Study in Postmenopausal Women with Osteoporosis), published in 2016, compared romosozumab to placebo in 7,180 postmenopausal women. At 12 months, romosozumab reduced new vertebral fractures by 73% compared with placebo (incidence: 0.5% vs. 1.8%, P<0.001) [8]. Lumbar spine BMD increased by 13.3% with romosozumab versus 0% with placebo at 12 months.

A cardiovascular safety signal emerged in ARCH: adjudicated major adverse cardiovascular events (MACE) occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients over the treatment period. The FDA's prescribing label includes a boxed warning advising against use in patients who have had a myocardial infarction or stroke within the preceding year [9]. Dr. Felicia Cosman, professor of clinical medicine at Columbia University, has stated: "The cardiovascular signal in ARCH needs to be weighed against the substantial fracture reduction. For patients at very high skeletal risk and low cardiovascular risk, romosozumab remains an appropriate first-line anabolic agent" [3].

Maryland prescribers should screen for cardiovascular risk factors before initiating romosozumab, consistent with the AACE and Endocrine Society recommendations [7].

Transitioning After Romosozumab: What Maryland Patients Should Know

Romosozumab is a 12-month, time-limited treatment. Gains in bone density begin to decline if no antiresorptive follow-up therapy is started.

Data from the FRAME extension study showed that patients who transitioned from romosozumab to denosumab maintained BMD gains at the lumbar spine (total increase of 17.6% from baseline at 24 months), while those who switched from placebo to denosumab gained only 7.2% over the same period [10]. This sequencing effect is why treatment guidelines emphasize planning the antiresorptive transition before starting romosozumab.

In Maryland, denosumab (Prolia) is covered by most insurance plans with PA, and the Amgen co-pay card program for Prolia operates similarly to the Evenity program. Bisphosphonates (alendronate, risedronate, zoledronic acid) are available as generics and represent a lower-cost follow-up option. Oral alendronate costs as little as $4 to $10 per month at Maryland pharmacies.

Patients should schedule their first antiresorptive dose within one month of the final romosozumab injection. Delaying beyond 30 days allows measurable BMD loss, particularly at the hip [10].